III期ReSPECT研究已完成入组，该研究旨在预防接受异基因血液和骨髓移植的成人患者发生真菌感染 ReSPECT研究的主要结果预计将于2026年中期公布 英国剑桥--(BUSINESS WIRE)--(美国商业资讯)-- Mundipharma今日宣布，正在进行的全球III期ReSPECT试验已完成患者招募，该试验 ...

Black Book survey reveals just 1 in 4 hospitals can fully exchange patient data across national boundaries in Q4 2025 VIENNA, ...

Challenges and New Momentumchina’s pharmaceutical innovation goes global challenges and new momentumIn the first five months ...

October 21, 2025 - Nanoform Finland Plc (“Nanoform”), a leading nanoparticle medicine performance-enhancing company, today announced that key findings from two proof-of-concept studies conducted in ...

Funds build on close to €30M in legacy support to advance Exeliom’s immunomodulator program, EXL01, addressing cancers, inflammatory and infectious diseases Paris, France, October 21, 2025 — Exeliom ...

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients[i] New findings from this investigational study build on the strength of the data for amivantamab in ...

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...

Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 monthsCHICAGO, USA and OXFORD, UK October 20th 2025 – ...

Successful inspections maintain 19 years of quality and transparency ~Contract research organisation and scientific consultancy Broughton has successfully hosted inspections by the United Kingdom ...

Latest analysis of U.S. real-world evidence demonstrates improved clinical outcomes when cefiderocol is used as earlier ...

Zoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation ...

Management to Showcase Full Nature-Cide Product Line at Industry's Flagship Event LOS ANGELES, CA / ACCESS Newswire / October ...